Aurobindo Pharma's Hyderabad unit gets 9 USFDA observations

Drug firm Aurobindo Pharma on Monday said the US health regulator has issued 9 observations after inspection of its unit 4 formulation facility in Hyderabad. The United States Food and Drug Administration (USFDA) has conducted an inspection at the company's unit 4, a formulation manufacturing facility in Hyderabad from February 12 to February 20, 2018, Aurobindo Pharma said in a BSE filing. (Text: PTI)